The startup develops gastrointestinal technologies that utilize neuromodulation and bioelectronic stimulation to treat gastrointestinal motility disorders such as chronic constipation, irritable bowel syndrome with constipation, and gastroparesis. These technologies aim to improve gastrointestinal function, enabling patients to experience enhanced digestive health and quality of life.
Funding
$19.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with chronic gastroparesis, irritable bowel syndrome with constipation, and other gastrointestinal motility disorders often experience debilitating symptoms such as nausea, vomiting, bloating, and abdominal pain. Existing treatments, including diet modifications and medications, may not provide adequate relief for many patients. This can significantly impact their quality of life and ability to maintain proper nutrition.
Solution
Enterra Medical provides the Enterra Therapy System, an implantable device designed to alleviate chronic, drug-resistant nausea and vomiting associated with gastroparesis of diabetic or idiopathic origin. The system utilizes gastric electrical stimulation (GES) to gently stimulate the smooth muscles of the lower stomach, helping to control these symptoms. Unlike other surgical options, Enterra Therapy is customizable, allowing physicians to adjust the level of stimulation non-invasively to meet individual patient needs. The therapy is also reversible, as the device can be turned off or surgically removed if needed.
Target Audience
The primary audience includes patients aged 18-70 years suffering from chronic, drug-resistant nausea and vomiting associated with gastroparesis caused by diabetes or an unknown origin, as well as gastroenterologists and surgeons specializing in gastroparesis treatment.
Features
- Implantable neurostimulator placed beneath the skin in the lower abdominal region
- Two leads that connect the neurostimulator to the stomach muscles
- External programming device for non-invasive adjustment of stimulation levels by a physician
- Mild electrical pulses delivered to the stomach muscles to help control nausea and vomiting
- Reversible therapy, allowing the device to be turned off or surgically removed
- Humanitarian Device Exemption (HDE) from the FDA for treatment of gastroparesis
- Patient identification card for airport travel and emergencies